Sign in
Stories
Addex Therapeutics Enters ADS Offering Agreement and Advances Clinical Trials
Share
Addex Therapeutics Meeting
Addex Therapeutics to Participate in Bio...
Addex Therapeutics: Financial Updates an...
ADOCIA Files 2023 Registration Document
ANJESO Drug Insight and Market Forecast
Adial Pharmaceuticals Raises Capital for...
Overview
API
Addex Therapeutics enters into an At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC for potential sales of ADSs up to $2.1 million. ADX71149, their lead drug candidate, is in a Phase 2 clinical trial for epilepsy treatment. Indivior PLC has licensed Addex's GABAB PAM program for substance use disorder drug candidates.
Ask a question
How does ADX71149 differ from other epilepsy treatments?
What are the implications of Indivior PLC's license for Addex's GABAB PAM program?
What are the potential benefits of the At-The-Market Offering Agreement for Addex Therapeutics?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage